Discovery & Development Timeline

But was he the first?- Egyptians drank tetracycline beer!

The rise of resistance & classification

Resistance emerged quickly:

• First resistance: 1953 (Shigella dysenteriae)
• Non-clinical uses (animal feed) accelerated spread
• Led to 33+ resistance genes (“tetracycline resistome”)

Classification by half-life:

Core structure

All tetracyclines share: Four-benzene ring structure (hydronaphthacene nucleus)

• Substitutions at C-5, C-6, C-7 determine properties

Cell Entry:

• Gram-negative: Mg²⁺-cation complex → OmpF/OmpC porins → accumulates in periplasm
• Gram-positive: Active transport through cytoplasmic membrane (ΔpH dependent)

Ribosomal binding & protein synthesis inhibition

Tetracyclines reversibly bind to the 30S ribosomal subunit → bacteriostatic…although clinical importance of bacteriostatic vs. cidal is debated. Free drug AUC/AUC is the PK/PD driver of activity- Killing (or growth suppression) depends on overall exposure, not peak concentration [6].

Absorption: key differences

Clinical pearl

The critical cation interaction

Problematic agents: Aluminum, magnesium, calcium (antacids), iron, zinc, multivitamins

Solution: Separate administration by 3 hours

Patient counseling:

• Take tetracycline 1 hour before OR 2 hours after meals
• Separate from antacids by 2-3 hours
• Dairy products (milk, yogurt, cheese) also chelate

Distribution & elimination

Tissue penetration

Doxycycline achieves excellent levels in:

• Bronchial secretions, pleural fluid
• Sinus, middle ear secretions
• Bone, prostate, testes
• Partically excreted in active form in urine

Minocycline uniquely penetrates:

• CSF (11-57% of serum levels)
• Saliva and tears
• Sebum (explaining efficacy in acne)

Special populations

Renal impairment:

• Tetracycline: Avoid (accumulates, worsens azotemia)
• Doxycycline: No adjustment needed (Biliary secretion → fecal excretion)
• Minocycline: No adjustment needed

Hepatic impairment:

• All tetracyclines: Use with caution
• Tigecycline: Reduce dose in Child-Pugh C

Gram-positive coverage

Generally susceptible:

• Streptococcus pneumoniae (resistance varies: 20-40%)
• Streptococcus pyogenes
• Many Enterococcus faecalis
• MRSA (community-acquired strains often susceptible)
• Listeria monocytogenes
• Nocardia, Actinomyces

Gram-negative coverage

Susceptible organisms:

• Haemophilus influenzae
• Brucella species
• Vibrio species (cholera)
• Yersinia pestis (plague)
• Francisella tularensis (tularemia)
• Pasteurella multocida (animal bites)

Limited or resistant:

• Pseudomonas aeruginosa - inherently resistant
• Proteus species - often resistant
• Enterobacterales - variable, increasing resistance

Atypical pathogens

Excellent activity against:

Anaerobes & other organisms

Anaerobic coverage:

• Moderate activity against many mouth anaerobes
• Bacteroides fragilis: variable (50-70% susceptible)
• Tigecycline: broader anaerobic coverage

Additional coverage:

• Treponema pallidum (syphilis - alternative to penicillin)
• Plasmodium spp. (malaria prophylaxis/treatment)
• Bacillus anthracis (anthrax)
• Actinomyces, Nocardia

Respiratory tract infections

Community-Acquired Pneumonia (CAP):

• Covers atypicals (M. pneumoniae, C. pneumoniae, Legionella)
• Alternative when macrolide resistance is a concern
• Dose: 100 mg BID × 5-7 days

Other respiratory uses:

• Acute exacerbations of COPD
• Psittacosis (C. psittaci)

Tick-borne diseases

Doxycycline is first-line for:

Sexually transmitted infections

Skin & soft tissue infections

Community-acquired MRSA SSTI:

• Doxycycline 100 mg BID or Minocycline 100 mg BID
• Duration: 5-10 days depending on severity

Acne vulgaris:

Infections requiring combination therapy

Brucellosis:

• Doxycycline 100 mg BID × 6 weeks + Streptomycin (or Gentamicin) × 2-3 weeks
• OR Doxycycline + Rifampin × 6 weeks

Q Fever:

• Acute: Doxycycline 100 mg BID × 14 days
• Chronic/Endocarditis: Doxycycline + Hydroxychloroquine × 18-24 months

Anthrax (post-exposure):

• Doxycycline 100 mg BID × 60 days (with vaccine if available)

Other important indications

Malaria prophylaxis:

• Doxycycline 100 mg daily (start 1-2 days before, continue 4 weeks after)
• Alternative to mefloquine or atovaquone-proguanil

Cholera:

• Single dose doxycycline 300 mg reduces duration

Periodontitis:

• Sub-antimicrobial doxycycline (20 mg BID) as adjunct to scaling

SIADH:

• Demeclocycline 600-1200 mg/day (induces nephrogenic DI)

Gastrointestinal effects

Most common adverse effects:

• Nausea, vomiting, diarrhea (dose-related- peak concentration drive for IV tigecycline, can be reduced with splitting dosing- for oral doxycycline. GI effects are related to local irritation)
• Esophageal irritation and ulceration

Management strategies:

• Take with food (doxycycline, minocycline)
• Use enteric-coated formulations
• Consider dose reduction if tolerating lower doses

Photosensitivity

Risk ranking:

• Highest: Demeclocycline > Doxycycline > Tetracycline
• Lowest: Minocycline (rare)

Patient counseling:

• Avoid prolonged sun exposure
• Use SPF 30+ sunscreen
• Wear protective clothing
• Reaction occurs within minutes to hours of UV exposure

Dental & bone effects

Dental effects:

• Permanent yellow-brown staining
• Enamel hypoplasia
• Risk greatest during tooth development (in utero through age 8)

Bone effects:

• Deposit in calcifying tissues
• Reversible decrease in bone growth rate in fetus/young children
• Does not affect already-formed adult bone

CNS effects (Especially minocycline)

Vestibular effects (minocycline):

• Dizziness, vertigo, ataxia
• Occurs in 30-90% of patients
• More common in women
• Usually reversible within 48-72 hours of stopping

Other CNS effects:

• Benign intracranial hypertension (pseudotumor cerebri)
  • Headache, visual changes, papilledema
  • Risk increased with concurrent vitamin A, retinoids

Hepatotoxicity

Tetracycline-specific:

• Dose-related (usually with >2 g/day IV)
• Microvesicular fatty liver
• Historically seen in pregnant women with pyelonephritis
• Rarely reported with modern dosing

Tigecycline:

• Elevated LFTs in 5% of patients
• Cases of hepatic failure reported
• Contributes to FDA warnings

Minocycline-specific effects

Unique adverse effects:

Major drug interactions

Three major mechanisms

1. Efflux Pumps (most common):

• Tet(A), Tet(B), Tet(K), Tet(L), etc.
• Actively pump tetracycline out of cell
• Energy-dependent (proton motive force)
• Encoded on plasmids → easily transferable

2. Ribosomal Protection Proteins:

• Tet(M), Tet(O)
• GTPases that “rescue” ribosomes
• Release tetracycline from 30S binding site
• Dislodge drug without damaging ribosome

Resistance mechanisms (continued)

3. Enzymatic Inactivation:

• Tet(X) - NADPH-dependent monooxygenase
• Inactivates tetracycline by adding hydroxyl group
• Rare but concerning (can affect tigecycline)
• Tet(X3), Tet(X4) emerging as threat

Current resistance landscape:

• 33+ resistance genes identified
• Often carried on mobile genetic elements
• Multiple mechanisms may coexist

How newer tetracyclines overcome resistance

Key structural modifications:

• C-9 glycylamido group (tigecycline)
• Enhanced ribosomal binding affinity
• Steric hindrance prevents efflux pump recognition

Tigecycline (glycylcycline)

Key features:

• First glycylcycline (FDA approved 2005)
• IV only, 100 mg loading then 50 mg q12h
• Higher dose: 200 mg loading, then 100 mg daily (greater N&V)
• Broadest spectrum of tetracyclines

FDA-approved indications:

• Complicated skin/skin structure infections
• Complicated intra-abdominal infections
• Community-acquired bacterial pneumonia

Tigecycline: Clinical considerations

Advantages:

• Active against MRSA, VRE, ESBL-producers
• Excellent tissue penetration (Vd = 7-10 L/kg)
• Good anaerobic coverage

Limitations:

• Low serum concentrations → avoid for bacteremia
• No Pseudomonas activity
• High rate of nausea/vomiting (30%)- can be reduced by splitting doses (activity AUC/MIC driven, N&V is peak related)
• Increased mortality signal

When to consider:

• MDR intra-abdominal infections
• MDR skin infections when oral options inadequate
• Not for VAP, bloodstream infections, or diabetic foot infections

Eravacycline (fluorocycline)

Key features:

• Fluorocycline class (FDA approved 2018)
• IV only: 1 mg/kg q12h
• 2-4× more potent than tigecycline in vitro

FDA-approved indication:

• Complicated intra-abdominal infections

Advantages over tigecycline:

• More potent against Enterobacterales
• Similar spectrum but better MICs
• Better tolerability (less nausea)

Omadacycline (aminomethylcycline)

Key features:

• Aminomethylcycline class (FDA approved 2018)
• Both IV and oral formulations available
• Oral bioavailability: ~35%

FDA-approved indications:

• Community-acquired bacterial pneumonia
• Acute bacterial skin and skin structure infections

Omadacycline: Clinical use

Dosing:

Key advantages:

• Oral option for serious infections
• Activity against MRSA, atypicals
• Better tolerability than tigecycline
• No food effect on absorption (take on empty stomach)

Sarecycline (Narrow-Spectrum)

Unique positioning:

• FDA approved 2018 for acne vulgaris only
• Specifically designed narrow spectrum
• Less impact on gut flora than other tetracyclines
• Weight-based dosing (60-150 mg once daily)

Not indicated for infections!

• Lower activity against typical respiratory pathogens
• Designed to target Cutibacterium acnes

Comparing newer tetracyclines

Historical context & mechanism

History:

• Discovered 1947 from Streptomyces venezuelae
• First antibiotic to be manufactured synthetically (1949)
• Fell from favor due to aplastic anemia

Mechanism:

• Binds 50S ribosomal subunit (NOT 30S like tetracyclines)
• Inhibits peptidyl transferase activity
• Prevents peptide bond formation
• Bacteriostatic (bactericidal against some organisms)

Chloramphenicol: Spectrum & Uses

Broad spectrum coverage:

• Gram-positives (including many resistant organisms)
• Gram-negatives (including H. influenzae, N. meningitidis)
• Anaerobes
• Rickettsiae, spirochetes

Current uses:

• Rickettsial infections (when doxycycline contraindicated)
• Bacterial meningitis (resource-limited settings)
• Ophthalmic infections (topical)
• Alternative for serious infections in beta-lactam allergy

Available formulations

Clinical decision making

Spectrum of Activity Summary

MIC Reference Values

Dosing Quick Reference